Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

842
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
842

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inherited human TFIIIA deficiency disrupts T cell development.

medRxiv : the preprint server for health sciences·2026
Same author

Absolute and relative intensity of physical activity after lung cancer surgery.

ERJ open research·2026
Same author

Marker-Agnostic Tumor Anchoring Chimeras Enable pH-Gated Immune Engagement.

Angewandte Chemie (International ed. in English)·2026
Same author

[Atoll sign: A CT finding with clinical impact].

Nederlands tijdschrift voor geneeskunde·2026
Same author

A Platform for High-throughput and Ultrasensitive Immunopeptidomics.

Molecular & cellular proteomics : MCP·2026
Same author

Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy.

Nature communications·2026

Related Experiment Video

Updated: Nov 15, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.5K

Dendritic Cell-Based Immunotherapy in Lung Cancer.

Dieter Stevens1,2, Joline Ingels3, Sandra Van Lint2,4

  • 1Respiratory Medicine - Thoracic Oncology Cluster, Ghent University Hospital, Ghent, Belgium.

Frontiers in Immunology
|March 8, 2021
PubMed
Summary

Dendritic cell immunotherapy shows promise for lung cancer treatment, enhancing immune responses beyond current checkpoint inhibitors. This review explores nearly two decades of research and future directions for this approach.

Keywords:
cancer vaccinedendritic cellimmune checkpoint blockadeimmunotherapylung cancertumor antigen

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.1K

Related Experiment Videos

Last Updated: Nov 15, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.1K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Lung cancer is a leading cause of cancer mortality globally.
  • Immune checkpoint inhibitors have advanced metastatic lung cancer treatment but benefit a minority of patients.
  • There is a need to enhance anti-tumoral immunity for broader patient benefit.

Purpose of the Study:

  • To review the 20-year experience with dendritic cell-based immunotherapy in lung cancer.
  • To summarize findings from early-phase clinical trials.
  • To discuss future perspectives for dendritic cell therapy in lung cancer.

Main Methods:

  • Review of early-phase clinical trials and scientific literature.
  • Analysis of dendritic cell function in initiating and regulating T cell responses.
  • Exploration of combination strategies with immune checkpoint blockade.

Main Results:

  • Dendritic cells are potent tools for initiating and regulating T cell responses.
  • Early trials have explored dendritic cell immunotherapy in various tumors, including lung cancer.
  • Despite challenges, dendritic cell therapy holds potential for enhancing anti-tumoral immunity.

Conclusions:

  • Dendritic cell-based immunotherapy is a promising strategy to overcome limitations of current lung cancer treatments.
  • Combining dendritic cell therapy with immune checkpoint inhibitors may harness the full anti-tumoral potential of the immune system.
  • Further research and clinical trials are needed to optimize dendritic cell immunotherapy for lung cancer patients.